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Abstract
Osteocytes, former osteoblasts buried within bone, are thought to orchestrate skeletal adaptation to mechanical stimuli.
However, it remains unknown whether hormones control skeletal homeostasis through actions on osteocytes. Parathyroid
hormone (PTH) stimulates bone remodeling and may cause bone loss or bone gain depending on the balance between
bone resorption and formation. Herein, we demonstrate that transgenic mice expressing a constitutively active PTH
receptor exclusively in osteocytes exhibit increased bone mass and bone remodeling, as well as reduced expression of the
osteocyte-derived Wnt antagonist sclerostin, increased Wnt signaling, increased osteoclast and osteoblast number, and
decreased osteoblast apoptosis. Deletion of the Wnt co-receptor LDL related receptor 5 (LRP5) attenuates the high bone
mass phenotype but not the increase in bone remodeling induced by the transgene. These findings demonstrate that PTH
receptor signaling in osteocytes increases bone mass and the rate of bone remodeling through LRP5-dependent and -
independent mechanisms, respectively.
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Introduction
Bone remodeling maintains the integrity of the skeleton by
continuously replacing packets of old bone with new through the
coordinated action of two cell types: osteoclasts that resorb bone,
followed by osteoblasts that form bone. The rate of bone
remodeling is determined by the number of osteoclasts and
osteoblasts; whereas the amount of bone present in the skeleton is
determined by the balance between resorption and formation [1].
Osteocytes, former osteoblasts buried within the bone matrix
during the process of bone deposition, are distributed throughout
bone in numbers that far exceed either osteoclasts or osteoblasts
[2,3]. Osteocytes are connected with each other and with cells on
the bone surface via cytoplasmic processes that travel along
tunnels within the mineralized bone [4]. Through this extensive
network, osteocytes sense variations in the level of mechanical
forces acting on bone and respond by signaling to osteoblasts,
osteoclasts, or both [5]. Osteocytes also perceive changes in the
levels of systemic factors as evidenced by the increased prevalence
of osteocyte apoptosis that occurs with glucocorticoid excess or
estrogen withdrawal [6–11], and increased osteocyte apoptosis
may itself decrease bone strength [12]. However, whether
hormones influence bone mass or the rate of bone remodeling
via actions on osteocytes has heretofore been unknown.
Sclerostin, the product of the Sost gene, is expressed exclusively
by osteocytes in bone [13–16]. Loss of sclerostin expression in
humans results in the high bone mass disorders Van Buchem’s
disease [17] and sclerosteosis [18], providing compelling evidence
that osteocytes can control bone mass. Moreover, targeted deletion
of the Sost gene in mice results in increased bone formation and
strength [19]; and administration of an anti-sclerostin antibody
increases bone formation and restores the bone lost after
ovariectomy in rodents [20]. Conversely, transgenic mice
overexpressing Sost exhibit low bone mass [13,21]. Sclerostin acts
in a paracrine manner to inhibit bone formation by binding to the
Wnt co-receptors LDL receptor-related protein (LRP) 5 and
LRP6, thereby antagonizing Wnt actions {13720, 14062, 15337},
such as induction of osteoblastogenesis, stimulation of pre-
osteoblast replication, and inhibition of osteoblast apoptosis [25–
27]. Thus, osteocytes exert negative feedback control of osteoblast
number and bone formation via production of sclerostin.
Abundant evidence from humans and experimental animals
indicates that parathyroid hormone (PTH) increases the rate of
bone resorption, and thereby the rate of bone remodeling. Thus,
chronic elevation of PTH levels increases bone resorption [28,29]
whereas patients with hypoparathyroidism [30] or rodents lacking
PTH [31,32] exhibit reduced bone resorption. The currently held
view is that PTH stimulates osteoclast formation by binding to its
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and thereby increases production of receptor activator of NFkB
ligand (RANKL) and macrophage colony stimulating factor (M-
CSF) and suppresses the RANKL decoy receptor osteoprotegerin
(OPG) [33–36]. Consistent with this notion, removal of the PTH
responsive region of the RANKL gene is sufficient to reduce the
rate of bone resorption, mimicking the effects of hypoparathy-
roidism [37]. Chronic PTH elevation also increases osteoblast
number and bone formation. This may occur indirectly through
stimulation of bone resorption which releases growth factors
embedded in the bone matrix and these in turn promote osteoblast
formation [38]. Intermittent administration of PTH as a therapy
to induce bone anabolism also increases osteoblast number, but
the mechanisms are thought to be different from those involved
with chronic PTH elevation [29,39].
Chronic PTH elevation, as in hyperparathyroidism, causes loss
of cortical bone. Cancellous bone is also lost with secondary
hyperparathyroidism caused by dietary calcium deficiency, but it is
preserved or even increased in primary hyperparathyroidism or
with activating mutations of PTHR1 [40,41]. Thus, PTH always
increases the rate of bone remodeling, but it can result in either
loss or gain of cancellous bone mass depending on the balance
between resorption and formation. The mechanisms underlying
these different outcomes of PTH action are unknown.
PTH related peptide (PTHrP) binds to PTHR1 and has
important actions during development [42]. Recent genetic studies
in mice demonstrate that PTHrP also acts postnatally to control
bone mass [43,44]. Thus, mice with PTHrP haploinsufficiency, or
with deletion of the PTHrP gene specifically from osteoblasts,
exhibit reduced bone formation due to increased osteoblast
apoptosis. In addition, the number of osteoclasts is reduced in
these animals most likely because of reduced RANKL expression.
Thus, activation of PTHR1 by either PTH or PTHrP increases
the rate of bone remodeling [45].
We and others have recently determined that PTH inhibits the
expression of the osteocyte specific gene Sost, raising the possibility
that the hormone stimulates bone formation via direct actions on
osteocytes [15,46]. Consistent with this idea, expression of PTHR1
has been demonstrated in osteocytes [47]. Here we demonstrate
that activation of PTHR1 signaling exclusively in osteocytes in
transgenic mice is sufficient to decrease sclerostin expression,
increase Wnt signaling, and increase bone mass. Unexpectedly,
PTHR1 activation in osteocytes also accelerates the rate of bone
remodeling. Remarkably, deletion of the Wnt co-receptor LRP5
attenuates the high bone mass phenotype induced by the
transgene, but does not affect the increased remodeling. Thus,
PTH signaling in osteocytes stimulates the accrual of bone mass
and increases the rate of bone remodeling by LRP5-dependent
and -independent mechanisms, respectively. Hence, the skeletal
effects of PTH and PTHrP may be due in part to previously
unrecognized actions of PTHR1 activation in osteocytes.
Results
Mice Expressing a Constitutively Active PTHR1 in
Osteocytes Exhibit High Bone Mass
To determine whether hormonal signaling in osteocytes is
sufficient to alter skeletal homeostasis, we generated transgenic
mice expressing a constitutively active form of human PTHR1
[48] specifically in osteocytes using the dentin matrix protein-1
(DMP1) promoter (DMP1-caPTHR1 mice) (Figure 1A). This
promoter was previously shown to direct osteocyte-specific
expression of transgenes in mice [5,49–52]. Expression of the
DMP1-caPTHR1 transgene was detected in bone tissues (L5
Figure 1. Generation of DMP1-caPTHR1 Transgenic Mice. (A) Schematic representation of the DMP1-caPTHR1 transgene. The transgene
contains the cDNA encoding the H223R constitutively active mutant of PTHR1 (caPTHR1) inserted downstream from a 12-kb DNA fragment
containing 8 kb of the murine DMP1 59-flanking region, first exon, first intron, and 17 bp of exon 2; a synthetic polyadenylation site was inserted
downstream from the caPTHR1 sequence. Arrows indicate the sites recognized by primers used for genotyping. (B) Quantitative RT-PCR analysis of
DMP1-caPTHR1 mRNA from the 5
th lumbar vertebrae (L5), tibia, and soft tissues of 10.5-week-old mice, normalized to the housekeeping gene
ribosomal protein S2. Bars represent the mean6SD of 4 mice. (C) Expression of the human PTHR1, murine PTHR1, and Sost determined by
quantitative RT-PCR in freshly isolated osteoblast-enriched (GFP2) and osteocyte-enriched (GFP+) cell preparations obtained from neonatal mice
without (WT) or with (TG) the DMP1-caPTHR1 transgene.
doi:10.1371/journal.pone.0002942.g001
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(Figure 1B). To confirm osteocyte-specific expression of the
transgene, hemizygous DMP1-caPTHR1 transgenic mice were
crossed with homozygous DMP1-GFP transgenic mice in which
GFP is expressed only in osteocytes [15,49,50], and gene expression
was examined in GFP-positive and GFP-negative cell populations
obtained from neonatal calvaria as detailed in Materials and
Methods (Figure 1C). In two independent experiments
(Figures 1C and S1A), transcripts for the DMP1-caPTHR1
transgene were found only in cells obtained from DMP1-caPTHR1
transgenic mice and were highly enriched in the GFP-positive,
osteocyte fraction. In contrast, murine PTHR1 mRNA levels were
similar in GFP-positive and GFP-negative cell populations in mice
with and without the DMP1-caPTHR1 transgene. Expression of the
osteocyte-specific gene Sost was enriched in the GFP-positive cells
obtained from mice with or without the DMP1-caPTHR1
transgene. Furthermore, consistent with previous findings demon-
strating that PTH inhibits Sost expression [15,46], Sost mRNA was
lower in osteocytes obtained from DMP1-caPTHR1 mice. These
results demonstrate that the DMP1-caPTHR1 transgene was
expressed exclusively in osteocytes.
DMP1-caPTHR1 transgenic mice were born at the expected
Mendelian frequency, were fertile, exhibited normal size and weight
(Figure S1B), but displayed increased radiodensity in regions of the
skull and long bones at 4 weeks of age (Figure 2A). Serial
measurement of bone mineral density (BMD) by dual-energy x-ray
absorptiometry (DEXA) revealed a remarkable and progressive
increase in bone mass in the appendicular and axial skeleton in
transgenic mice of both sexes compared to wild type littermates
(Figure 2B and S1C). Femoral BMD was 63% higher than wild
type littermates at 8 weeks of age and 109% higher at 24 weeks.
Increased bone mass in the transgenic mice was maintained until at
least 8 months of age (Figure S1D). Micro-CT of femur and
vertebra of 10-week-old transgenic mice confirmed the high bone
mass phenotype (Figure 2C). Cross-sectional area of the femur at
both the distal metaphysis and midshaft was elevated by approxi-
mately 2-fold. Increased bone was also observed in the calvaria, a
bone that is formed by intramembranous ossification (Figure 2C).
Abundant bone tissue and increased mineral was revealed by
staining with hematoxylin & eosin or von Kossa (Figures 2D and
2E). This high bone mass phenotype was also present in a second
line of DMP1-caPTHR1 transgenic mice (Figure S1E).
DMP1-caPTHR1 Mice Exhibit Elevated Bone Remodeling
The high bone mass phenotype of DMP1-caPTHR1 transgenic
mice was present as early as 3 days after birth, had progressed by
3.5 weeks of age (Figure S2), and appeared maximal before 12
weeks of age (Figure S3). To determine the cellular basis of the
increased bone mass, we performed histomorphometric measure-
ments of cancellous bone of the distal femur in 3.5-week-old mice.
This age was selected for histomorphometric analysis because, in
contrast to mice at older ages, a large amount of cancellous bone
surface was available for analysis and the cellular processes leading
to increased bone mass must have still been occurring. Cancellous
bone area and trabecular width were increased in femoral bone of
the transgenic mice (Figure 3A and B, and Table S1); however,
trabecular spacing and number were not significantly different
from wild type littermates. Both osteoblast and osteoclast
perimeters were elevated by more than 2-fold in transgenic mice,
whereas the number of osteocytes per cancellous bone area
(osteocyte density) was unchanged (Figure 3C). This increase in
the numbers of osteoclasts and osteoblasts, and thus the rate of
bone remodeling, was reflected by a decrease in quiescent surface
(Figure 3D). The DMP1-PTHR1 transgenic mice also exhibited
diffuse incorporation of the fluorochromes (Figure 3E). There-
fore, quantification of the rate of bone formation was not possible.
The presence of diffuse labels could be due to rapid bone
formation leading to woven bone, which was indeed revealed by
polarized light microscopy (Figure 3E). However, abnormal
mineralization cannot be excluded since osteoid surface was also
elevated in the transgenic mice (Table S1). Nevertheless, and
consistent with the elevated osteoblast number and expected high
bone formation rate, circulating osteocalcin was elevated in
DMP1-caPTHR1 mice (Figure 3F). Moreover, in line with the
increase in osteoclast perimeter, plasma levels of carboxy-terminal
crosslinked telopeptide of type I collagen (CTX) and urinary levels
of deoxypyridinoline (DPD), markers of bone resorption, were also
elevated in the transgenic mice (Figure 3F). No significant
changes were found in circulating levels of calcium, inorganic
phosphate, or PTH (Figure S4), measured as indicated in the
Supplementary Methods (Text S1) section. The increase in
osteoblast number induced by the transgene was associated with a
decrease in the prevalence of osteoblast apoptosis (Figure 3G). In
contrast, osteocyte survival was not affected (Figure 3G). The
number of mesenchymal progenitors or committed osteoblast
progenitors in the bone marrow, as measured by colony forming
Figure 2. DMP1-caPTHR1 Mice Exhibit High Bone Mass. (A)
Radiographs of 4-week-old female wild type (WT) and DMP1-caPTHR1
transgenic (TG) mice. (B) Femoral and spinal BMD in WT and TG female
mice, measured at 4 wk intervals up to 24 wks of age. Symbols
represent the mean6SD of 5 mice. * p,0.05 vs. WT mice at each time
point. (C) Representative longitudinal and cross-sectional micro-CT
images of femur, 4th lumbar vertebra, and calvaria obtained from 10.5-
week-old female WT and TG mice. (D) Hematoxylin and eosin staining
of tibial and (E) von Kossa staining of femoral bone sections from 10.5-
week-old WT and TG mice.
doi:10.1371/journal.pone.0002942.g002
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respectively, was not increased in the transgenic mice (Figure 3H).
These results indicate that PTHR1 activation in osteocytes leads to
an increased rate of bone remodeling with a positive balance
resulting in more bone, associated with reduced prevalence of
osteoblast apoptosis.
Sost and Sclerostin Expression are Reduced and Wnt
Signaling is Increased in DMP1-caPTHR1 Mice
Quantitative RT-PCR and in situ hybridization demonstrated
an increase in the mRNAs encoding osteocalcin, collagen 1a1, and
osteopontin in bones from DMP1-caPTHR1 mice compared to
wild type littermates (Figure S5A and B, and Supplementary
Methods section). Furthermore, expression of the osteoclast-
specific genes cathepsin K, tartrate resistant acid phosphatase
(TRAPase), and calcitonin receptor was also elevated in the
transgenic animals (Figure S5C). On the other hand, DMP1-
caPTHR1 transgenic mice exhibited a striking decrease in Sost
transcripts and sclerostin protein, as determined by quantitative
RT-PCR, Western blot analysis, and immunohistochemistry
(Figure 4A, B and C). Increased b-galactosidase activity in
bones from the DMP1-caPTHR1 mice crossed with Wnt-
responsive reporter mice (TCF-bGal) demonstrated that decreased
Sost and sclerostin expression were associated with elevated Wnt
signaling in vivo (Figure 4D). Furthermore, expression of the
Wnt/b-catenin target genes Axin 2, SMAD6, BMP4, and naked
[53–55] was elevated in DMP1-caPTHR1 transgenic mice
(Figure 4E). OPG, another gene regulated by Wnt/b-catenin
signaling [56,57], was also slightly elevated, although this increase
did not reach statistical significance (Figure 4F). In contrast,
RANKL and M-CSF, cytokines that control the magnitude of
osteoclast formation, were significantly increased in DMP1-
caPTHR1 transgenic mice (Figure 4F).
Figure 3. DMP1-caPTHR1 Transgenic Mice Have Increased Bone Turnover. (A–D) Histomorphometric measurements were determined in
the distal femur, excluding the growth plate, of 3.5-week-old DMP1-caPTHR1 mice (TG) and wild type littermates (WT). Both sexes were included.
Bone area (A), trabecular architecture (B), osteoblast perimeter, osteoclast perimeter, and osteocyte density (C), and quiescent surface (D) are
shown. (E) Distal femoral cancellous bone of WT or TG mice viewed with epifluorescence to reveal calcein and alizarin labels or with polarized light
with a rose quartz plate to reveal collagen architecture (6200). (F) Serum osteocalcin, serum CTX, and urinary DPD were measured in 3.5- to 5-week-
old mice. (G) Osteoblast and osteocyte apoptosis measured in femoral sections from 3.5-week-old mice. (H) CFU-F and CFU-OB obtained from bone
marrow cells of 4.5-week-old mice. Bars represent the mean6SD of 3–5 mice. * p,0.05 vs. WT mice.
doi:10.1371/journal.pone.0002942.g003
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but not to the Increased Remodeling, of DMP1-caPTHR1
Mice
To determine whether inhibition of Sost gene expression in
osteocytes and the resulting increase in Wnt signaling was indeed
responsible for the high bone mass phenotype exhibited by DMP1-
caPTHR1 mice, these mice were crossed with mice lacking the
Wnt co-receptor LRP5 (LRP52/2), which display a low bone
mass phenotype due to reduced osteoblast number and activity
[58–60]. Sost mRNA expression in DMP1-caPTHR1;LRP52/2
mice was still suppressed compared to LRP52/2 mice lacking the
transgene (0.3760.23 versus 2.0061.16, p,0.05), eliminating the
possibility that the absence of LRP5 interfered with the ability of
the transgene to decrease Sost in osteocytes. Serial BMD
measurements confirmed the progressive increase in bone mass
between 4 and 12 weeks of age in the femur and spine of DMP1-
caPTHR1 mice in a LRP5+/+ background compared to wild type
littermates (Figure 5A). In contrast, DMP1-caPTHR1 transgenic
mice in a LRP52/2 background exhibited BMD similar to
LRP52/2 littermates lacking the transgene (Figure 5A). The
blunting of the effect of the transgene in mice lacking LRP5 was
confirmed by Von Kossa staining and high resolution micro-CT at
12 weeks of age (Figure 5B and C). Micro-CT images also
revealed that the transgene was still able to increase cancellous
bone in animals lacking LRP5, however this effect was greatly
reduced compared to animals expressing LRP5 (Figure 5C). This
persistent increase in bone induced by the transgene in animals
lacking LRP5 could be due to increased Wnt signaling through
LRP6. In addition, bone material density as measured by micro-
CT was decreased by the transgene regardless of the LRP5
genotype (Figure 6A). This may explain why the increased
cancellous bone in DMP1-caPTHR1;LRP52/2 mice detected by
micro-CT did not result in increased BMD as measured by DEXA
(Figure 5A).
Despite the reduced ability of the transgene to increase bone
mass in the absence of LRP5, circulating levels of CTX and
osteocalcin remained elevated in DMP1-caPTHR1;LRP52/2
Figure 4. Sost and Sclerostin Expression are Decreased and Wnt Signaling is Increased in DMP1-caPTHR1 Transgenic Mice. (A)
Quantitative RT-PCR analysis of Sost mRNA in tibia from 9-week-old DMP1-caPTHR1 mice and wild type littermates (n=3). Both sexes were included.
(B) Sclerostin protein levels were determined by Western blot analysis of lysates from the 6th lumbar vertebrae of 9-week-old wild type (WT) and
DMP1-caPTHR1 (TG) mice. Each lane contains protein lysate from a single mouse. (C) Anti-sclerostin immunohistochemistry in ulnae sections from
10.5-week-old WT and TG mice. (D) b-galactosidase activity was measured in lysates of femurs obtained from 4.5-week-old TCF-bgal reporter mice
with and without the DMP1-caPTHR1 transgene, and is expressed as relative luminescence units (RLU)/200 mg protein (n=3–5 mice/group).
Quantitative RT-PCR analysis of the indicated Wnt target genes (E), and OPG, RANKL, and M-CSF (F), in tibia from 8-week-old DMP1-caPTHR1 mice
and wild type littermates. Bars represent the mean6SD of 3 mice. * p,0.05 vs. WT mice.
doi:10.1371/journal.pone.0002942.g004
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significantly lower than the one induced by the transgene in the
LRP5+/+ background. Consistent with a high rate of bone
resorption, the DMP1-caPTHR1;LRP52/2 mice still exhibited
increased cortical porosity (Figure 5B and C). Furthermore,
DMP1-caPTHR1;LRP52/2 mice showed the same abundant
and diffuse fluorochrome incorporation observed in DMP1-
caPTHR1 mice with intact LRP5 signaling (Figure 6C). This
phenomenon, as well as the reduced bone material density, may be
due to the formation of woven bone [61], abnormal mineralization
[51], or both.
Taken together, these results suggest that activation of the PTH
receptor in osteocytes results in two separate effects: one that leads
to increased bone mass and that depends in part on LRP5
signaling to favor bone formation, and another that results in
increased bone remodeling independent of LRP5 signaling.
Discussion
The concept that PTH can act directly on osteocytes was
proposed in the 1970’s based on evidence that injected
radiolabeled-PTH localizes in osteocytes and that the hormone
changes osteocyte morphology [62,63]. Recently we and others
have shown that PTH suppresses the expression of the osteocyte-
specific product sclerostin, an antagonist of Wnt signaling [15,46].
This evidence, together with the well documented role of Wnt
Figure 5. The High Bone Mass Phenotype of the DMP1-caPTHR1 Mice is Ameliorated in Mice Lacking the Wnt Co-Receptor LRP5. (A)
Serial analysis of BMD in the femur and spine of LRP5+/+ and LRP2/2 mice, with and without the DMP1-caPTHR1 transgene. Both sexes were
included. Bars represent the mean6SD of 3–5 mice/group. * p,0.05 vs. LRP5+/+ mice without the transgene. # p,0.05 vs. LRP+/+ mice without the
transgene. (B) Von Kossa staining of femurs and lumbar vertebrae of 12-week-old LRP5+/+ and LRP2/2 mice, with and without the DMP1-caPTHR1
transgene. (C) High resolution micro-CT scans of distal femora from LRP5+/+ and LRP2/2 mice, with and without the DMP1-caPTHR1 transgene.
doi:10.1371/journal.pone.0002942.g005
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PTH may control the production of osteoblasts through actions on
osteocytes. In the present report, we have addressed the functional
consequences of PTH actions in osteocytes by taking advantage of
a fragment of the DMP1 promoter that confers osteocyte-specific
expression of transgenes [5,49,52,64]. The evidence presented
herein demonstrates that PTH receptor signaling exclusively in
osteocytes is sufficient to increase osteoblast number and
dramatically increase bone mass via down-regulation of sclerostin
and thereby elevation of LRP5 signaling. Remarkably, activation
of PTHR1 in osteocytes also caused an increase in bone
resorption, and thereby the rate of bone remodeling. This effect
of PTH was previously attributed to its actions on stromal/
osteoblastic cells [34,41]. Thus, our findings reveal for the first
time that osteocytes could be the targets and mediators of the two
most important effects of PTH on bone (Figure 7). Whether this
is the case outside the context of the genetic manipulation used
here will await osteocyte-specific deletion of the PTH receptor.
PTH can clearly increase bone mass when administered
intermittently, and this effect has been attributed by us to a direct
and potent anti-apoptotic effect of the hormone on osteoblasts
[29,39,65]. In the present report, we determined that the increased
osteoblast number and bone formation caused by PTH signaling
exclusively in osteocytes is also associated with decreased osteoblast
apoptosis. Attenuation of osteoblast apoptosis in our model can be
readily explained by unleashing Wnt signaling secondary to
suppression of Sost expression. Indeed, several studies demonstrate
that Wnt signaling increases osteoblast number and bone formation
at least in part by inhibiting osteoblast apoptosis. Specifically, the
increased bone mass observed in mice deficient in the Wnt
antagonist secreted frizzled related protein-1 (SFRP-1), or mice
expressing a LRP5 mutant (G171V) unable to bind sclerostin, is
associated with decreased osteoblast and osteocyte apoptosis [66–
68]. Moreover, direct activation of Wnt signaling in vitro prevents
apoptosis of osteoblastic cells [27].
Besides the anti-apoptotic effects of Wnts in the increased bone
mass of the DMP1-caPTHR1 mice, the unleashing of Wnt
signaling in this model may have had additional effects on cells of
the osteoblastic lineage. We did not find an increase in the number
Figure 6. The High Bone Remodeling Phenotype of DMP1-caPTHR1 Mice does not Require LRP5. (A) Osteocalcin and CTX measured in
plasma from 12-week-old LRP5+/+ and LRP2/2 mice, with and without the DMP1-caPTHR1 transgene. Both sexes were included. (B) Bone material
density as determined by micro-CT analysis of femurs from LRP5+/+ and LRP2/2 mice, with and without the DMP1-caPTHR1 transgene. Bars
represent the mean6SD of 3–5 mice/group. * p,0.05 vs. LRP5+/+ mice without the transgene; # p,0.05 vs. LRP5+/+ mice with the transgene. (C)
Representative images of histologic sections showing calcein and alizarin double labeling in femurs from LRP5+/+ and LRP2/2 mice with and
without the DMP1-caPTHR1 transgene.
doi:10.1371/journal.pone.0002942.g006
Figure 7. PTHR1 Signaling in Osteocytes Leads to Increased
Bone Mass and Remodeling via Distinct Mechanisms. In the
proposed model, PTHR1 signaling in osteocytes activates at least two
distinct pathways: one leading to increased bone mass and the other
leading to increased bone remodeling. Suppression of Sost/sclerostin
and activation of LRP5 signaling increase osteoblast numbers and are
required for the increase in bone mass. The elevation of bone
resorption is independent of the Sclerostin/LRP5 pathway. The question
mark indicates uncertainty of the cellular source of RANKL and M-CSF
(osteocytes versus stromal/osteoblastic cells).
doi:10.1371/journal.pone.0002942.g007
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influence the very early stages of osteoblastogenesis. It is entirely
feasible, however, that Wnts also increased osteoblast number by
attenuating the apoptosis, stimulating the differentiation, or
increasing the proliferation of the progeny of CFU-OB, or a
combination of these mechanisms.
Targeted activation of the PTH receptor exclusively in
osteocytes also increased osteoclast number and bone resorption
and these changes were accompanied by an elevation of the levels
of RANKL and M-CSF, the two essential signals for osteoclas-
togenesis. Whether osteocytes are the source of these cytokines, or
whether an osteocyte-derived product stimulated the expression of
these cytokines in a paracrine fashion by altering their production
in stromal/osteoblastic cells, awaits further studies.
The results of the present studies with genetically modified mice
could well be relevant to the mechanisms underlying the changes
in bone cells that occur with hyperparathyroidism. Several skeletal
features of the DMP1-caPTHR1 mice are similar to those found in
patients with hyperparathyroidism, including a high rate of bone
remodeling, increased cancellous bone, and increased cortical
porosity [69]. Indeed, the cortical porosity and cancellous bone
were increased to such an extent that the junction between cortical
and cancellous bone could not be distinguished (Figure 2).
Erosion of the cortex, as well as the presence of woven bone, is also
seen in patients with secondary hyperparathyroidism in renal
osteodystrophy [69]. Therefore, some of the skeletal changes that
occur in humans with high levels of PTH may be due to direct
actions of the hormone on osteocytes.
T h es t r i k i n gb o n eg a i ni nD M P 1 - c a P T H R 1m i c ea n dt h eb l u n t i n g
of this effect in mice lacking LRP5 suggest that PTH signaling in
osteocytes promotes a positive balance within each remodeling unit
via suppression of Sost. Consistent with this contention, in
preliminary studies we found that DMP1-caPTHR1 mice that also
harbor a DMP1-Sost transgene do not exhibit high bone mass,
indicating that suppression of Sost is indeed required for the anabolic
effect of the DMP1-caPTHR1 transgene (data not shown).
In contrast to our findings demonstrating dramatic bone
anabolism with PTHR1 signaling exclusively in osteocytes, chronic
elevation of PTH systemically leads to bone loss or to only a modest
increase in cancellous bone. This difference may be explained by
actions of the hormone on mature osteoblasts and osteoblast
precursors that counter-balance osteocyte-mediated effects on bone
formation. Specifically, the prevalence of osteoblast apoptosis is
decreased in DMP1-caPTHR1 mice but not with chronic elevation
of PTH [29]. Yet, sclerostin is suppressed, and Wnt signaling is
elevated, in both conditions [15]. Therefore, it appears that Wnt
signalingisnotabletoinhibitapoptosisinacellinwhichthePTHR1
is continuously activated. Consistent with this, osteocyte apoptosis
was not suppressed inDMP1-caPTHR1 micelikelybecause the pro-
survival effects of Wnts were overridden by the simultaneous
PTHR1 signal, whereas osteoblast apoptosis was suppressed because
osteoblasts receive only Wnt pro-survival signals. Chronic elevation
of PTH may also suppress osteoblast differentiation and lead to
accumulation of immature osteoblasts. This effect could account for
the marrow fibrosis found insevere hyperparathyroidism [70] and in
transgenic mice expressing a constitutively active PTHR1 under the
control of a collagen 1a1 promoter fragment [41,71]. Maturational
arrest of osteoblastic cells was not observed in DMP1-caPTHR1
mice, indicating that this effect is due to PTHR1 activation in cells
other than osteocytes.
Resorption was still elevated in DMP1-caPTHR1 mice in a
LRP5-null background, supporting the contention that increased
Wnt signaling in these mice does not contribute to the increased
rate of bone remodeling. This is consistent with evidence that
models of elevated Wnt signaling, such as SFRP-1 knockout mice
or G171V-LRP5 transgenic mice, do not exhibit increased bone
resorption [66,67]. Moreover, administration of an anti-sclerostin
antibody as well as deletion of the Sost gene, maneuvers which
increase Wnt signaling through both LRP5 and LRP6, increased
bone formation but did not alter bone resorption [19,20].
In contrast to chronic elevation of PTH, daily injections of the
hormone induce bone anabolism. This mode of administration of
PTH is associated with a transient suppression of sclerostin
[15,46], which could result in increased Wnt signaling. Although
daily injections of PTH induced equivalent increases in femoral
BMD in LRP5-null and wild type mice [72,73], these animals
retained LRP6. Thus, the possibility that suppression of sclerostin
contributes to the anabolic action of intermittent PTH adminis-
tration will require additional studies.
The decreased bone formation exhibited by mice lacking
PTHrP in osteoblastic cells demonstrates that under physiological
conditions osteoblast/osteocyte-derived PTHrP promotes bone
formation in part by stimulating osteoblast differentiation and
survival [44]. Our studies raise the possibility that PTHrP
promotes bone formation postnatally via suppression of sclerostin
and stimulation of Wnt signaling. In particular, PTHrP might
contribute to the maintenance of skeletal mass by mechanical
forces. Indeed, PTHrP expression is increased in response to
mechanical stimulation of osteoblastic and osteocytic cell lines
[74]. And, we have shown that the anabolic response of bone
loading is associated with reduced sclerostin expression and that it
requires LRP5 signaling [72,73]. Taken together these findings
raise the possibility that local increase in PTHrP induced by
mechanical loading activates PTHR1 in osteocytes, thereby
reducing sclerostin expression and increasing bone formation.
In conclusion, this study expands the prevailing view of
osteocytes as mediators of the response of bone to mechanical
forces to one in which these cells also orchestrate changes in bone
mass and the rate of remodeling in response to hormones.
Materials and Methods
Generation of DMP1-caPTHR1 Transgenic Mice and Cross
with LRP5-Null Mice
DMP1-caPTHR1 transgenic mice were generated using a DNA
construct encoding the H223R mutant of the human PTHR1 [48]
inserted downstream from a 12 kb DNA fragment containing 8 kb
of the 59-flanking region, the first exon, the first intron, and 17 bp
of exon 2 of the murine DMP1 gene [49]. In addition, a 140 bp
fragment containing the rabbit beta-globin polyadenylation
sequence was inserted downstream from the H223R cDNA. The
DNA sequence of the transgene is available upon request.
Transgenic mice were produced by microinjection of purified
DNA into pronuclei of C57BL/6 mice at the transgenic mouse
core facility of the University of Arkansas for Medical Sciences.
DMP1-caPTHR1 transgenic mouse colonies were maintained by
breeding mice hemizygous for the transgene with wild type
C57BL/6 mice. All DMP1-caPTHR1 mice used in these studies
were hemizygous for the transgene. LRP5
2/2 mice [58] were
crossed with DMP1-caPTHR1 mice and the progeny were
intercrossed to obtain LRP5
+/+ and LRP5
2/2 mice with and
without the DMP1-caPTHR1 transgene. All mice were fed a
regular diet (Harlan/Teklad #7001) and water ad libitum and
maintained on a 12-hr light/dark cycle. Protocols involving
genetically modified mice and their wild type littermates were
approved by the Institutional Animal Care and Use Committees of
the University of Arkansas for Medical Sciences and the Central
Arkansas Veterans Healthcare System.
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Radiographic images were obtained from anesthetized mice
using a Faxitron X-ray system (AxR model MIIONH, Faxitron X-
ray Corp., Wheeling, IL) [75]. BMD was determined by DEXA
using a PIXImus densitometer (G.E. Medical Systems, Lunar
Division, Madison, WI) as previously described [28]. BMD
measurements included the entire thoracic and lumbar spine
(spinal BMD) or the entire femur (femoral BMD). For micro-CT
analysis, bones were dissected, cleaned of soft tissue and stored in
70% ethanol until analyzed using a Scanco model mCT40
instrument (Scanco Medical AG, Basserdorf, Switzerland) [76].
For histomorphometric analysis, femurs were dissected, fixed, and
embedded in methyl methacrylate. Static histomorphometric
analysis of non-decalcified bone sections was performed in the
distal femur, avoiding the growth plate, as previously described
[6]. Fluorochrome labeling of the bones was performed by
intraperitoneal injections of calcein (20 mg/kg, Sigma Chemical,
St. Louis, MO, USA) and alizarin (20 mg/kg, Sigma) adminis-
tered 8 and 3 days before sacrifice, respectively, as previously
described [72]. The terminology and units used are those
recommended by the Histomorphometry Nomenclature Commit-
tee of the American Society for Bone and Mineral Research [77].
Detection of apoptotic osteoblasts and osteocytes by in situ nick-
end labeling was performed as previously described [6,78].
Mineralized bone was visualized in non-decalcified, plastic-
embedded sections using the von Kossa stain, and decalcified,
paraffin embedded bone sections were stained with hematoxylin
and eosin, using standard histological procedures.
Bone Turnover Markers
Plasma osteocalcin and CTX were measured using an enzyme
radiometric assay (Biomedical Technologies, Soughton, MA) and
an enzyme linked immunosorbant assay (Immunodiagnostic
Systems Inc., Fountain Hills, AZ), respectively [29].
Osteocyte Isolation
Homozygous DMP1-GFP transgenic mice (provided by D. W.
Rowe) [49] were crossed with hemizygous DMP1-caPTHR1 mice
to generate DMP1-GFP-positive offspring with and without the
DMP1-caPTHR1 transgene. Calvaria cells were isolated from 3-
to 6-day-old mice using a modification of a previously described
protocol [15,29,79]. Briefly, bones from each mouse were
individually subjected to serial trypsin/collagenase digestions of
20 minutes each and fractions 2 through 9 were collected. Cells
obtained from mice exhibiting the same genotype were pooled and
GFP-expressing cells (enriched in osteocytes) were separated from
GFP-negative cells (enriched in osteoblasts) by immediately
subjecting the cell suspension to sorting using a FACSAria flow
cytometer (BD Biosciences, San Jose, CA) at the University of
Arkansas for Medical Sciences Flow Cytometry Core Facility.
RNA was isolated from the cells immediately after sorting.
Gene Expression Studies
Quantitative PCR. Total RNA was purified from cells or
tissues using Ultraspecreagent (Biotecx Laboratories,Houston, TX),
according to the manufacturer’s instructions. Taqman quantitative
RT-PCR was performed as previously described [75] using primer
probe sets from Applied Biosystems (Foster City, CA). Relative
mRNA expression levels were normalized to the house-keeping gene
ribosomal protein S2 using the DCt method [80].
Western Blot Analysis. Immunoblots were performed on
protein lysates prepared from vertebral bone (L6) as previously
described [15]. One hundred mg of protein lysate from individual
mice was separated on a 10% SDS gel and then transferred to
Immobilon membrane (Millipore, Billerica, MA). The membrane
was then incubated with goat polyclonal anti-mouse sclerostin
antibody (1:100 in 5% non fat milk) overnight at 4uC, followed by
incubation with rabbit anti-goat-HRP secondary antibody (1:2000
in 5% milk) for 1 hour at room temperature, and then developed
with enhanced chemiluminescence (Pierce Biotechnology, Inc.,
Rockford, IL).
Immunohistochemistry. Ulnae were fixed in neutral
buffered formalin, decalcified, and then embedded in paraffin.
Eight mm sections were incubated with goat polyclonal anti-mouse
sclerostin antibody (R&D Systems, Minneapolis, MN) diluted
1:100 in 2% rabbit serum, followed by rabbit anti-goat-HRP
conjugated secondary antibody (Santa Cruz Biotechnologies,
Santa Cruz, CA) diluted 1:200 in 2% rabbit serum, and
developed with a DAB substrate-chromogen system (Dako
Corp., Carpinteria, CA), as previously described [15,73].
Sections were washed and counterstained with methyl green.
TCF-bGAL Reporter Gene Assay. Homozygous TCF-bGAL
transgenicmice(JacksonLaboratories,Bar Harbor,ME) [81],which
contain a b-galactosidase reporter gene under the control of a TCF-
responsive promoter, were crossed with hemizygous DMP1-
caPTHR1 mice to obtain TCF-bGAL mice with or without the
DMP1-caPTHR1 transgene. b-galactosidase activity was
determined in femurs from 31-day-old mice using the Galacto-
Light kit (Applied Biosystems, Foster City, CA), as previously
described [82]. Bones were homogenized for 20 seconds in lysis
buffer and protein content was determined using the BioRad DC
protein assay kit (Hercules, CA). b-galactosidase activity was
expressed as relative fluorescent units/200 mg protein.
Assay for osteoblast progenitors. Bone marrow cells were
isolated from 4.5-week-old wild type and transgenic mice (8mice per
group). Four sets of 2 samples from different mice were pooled and
seeded at a density of 0.3610
6 cells/cm
2. CFU-F and CFU-OB
were developed in the presence of 1 mM L-ascorbic acid phosphate
magnesium salt n-hydrate (A2P, Wako Chemicals USA, Richmond,
VA) for 10 and 25 days, respectively, as previously published [83].
For the determination of CFU-F, colonies were stained for alkaline
phosphatase and counterstained with hematoxylin. Colonies of cells
containing a minimum of 20 cells were designated as CFU-F. For
the determination of CFU-OB, cultures were stained using Von
Kossa staining to visualize and enumerate colonies containing
mineralized bone matrix.
Statistical Analysis
Data were analyzed using SigmaStat (SPSS Science, Chicago,
IL). All values are reported as the mean6SD. Differences between
group means were evaluated with Student’s t test or ANOVA.
Supporting Information
Figure S1 Generation of DMP1-caPTHR1 Transgenic Mice (A)
Expression of the human PTHR1 (transgene), murine PTHR1,
and Sost, normalized to ribosomal protein S2, was determined by
quantitative RT-PCR in osteoblast-enriched (GFP2) and osteo-
cyte-enriched (GFP+) cell preparations from wild type or DMP1-
caPTHR1 transgenic mice. (B) Total body weight of female and
male DMP1-caPTHR1 transgenic mice and wild type littermates
measured every 4 weeks up to 24 weeks of age. Symbols represent
the mean6S.D. of 5 mice. (C) Serial measurement of femoral and
spinal BMD of male DMP1-caPTHR1 mice and wild type
littermates. Symbols represent the mean6S.D. of 3–5 mice. *
p,0.05 vs. WT mice for each time point. (D) Micro-CT image of
femurs from 8-month-old wild type and DMP1-caPTHR1 mice.
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caPTHR1malemicefromanindependent transgenicline,559.Bars
represent the mean6S.D. of 5 mice. * p,0.05 vs. WT mice.
Found at: doi:10.1371/journal.pone.0002942.s001 (0.19 MB TIF)
Figure S2 Micro-CT Analysis of 3-Day-Old and 3.5-Week-Old
DMP1-caPTHR1 Transgenic Mice (A) Representative longitudinal
and cross-sectional micro-CT images of femurs from 3-day-old
DMP1-caPTHR1 mice (TG) and wild type littermates (WT). Three
animals per genotype were analyzed. The total bone volume per
femur was measured. * indicates p,0.05 vs wild type littermates. (B)
Longitudinal and cross-sectional micro-CT images of femurs, 5th
lumbar vertebra, and calvaria from 3.5-week-old WT and TG mice.
Found at: doi:10.1371/journal.pone.0002942.s002 (0.35 MB TIF)
Figure S3 Hematoxylin & Eosin Staining of Longitudinal
Sections of Femoral Diaphysis of 4-, 8-, and 12-Week-Old
DMP1-caPTHR1 Transgenic Mice Decalcified, paraffin embed-
ded femurs were longitudinally sectioned and stained with
hematoxylin and eosin. Bars indicate 0.1 mm.
Found at: doi:10.1371/journal.pone.0002942.s003 (2.00 MB TIF)
Figure S4 Circulating levels of Calcium, Phosphate and PTH
are not altered in DMP1-caPTHR1 transgenic mice Plasma levels
of (A) total calcium, (B) inorganic phosphate, and (C) PTH in
DMP1-caPTHR1 mice and wild type littermates. Bars are
mean6S.D. (A) n=4 wild type and 5 transgenic 3.5-week-old;
(B) n=11 wild type and 16 transgenic 2.5-month-old mice; and (C)
n=5 wild type and 7 transgenic 2-month-old mice.
Found at: doi:10.1371/journal.pone.0002942.s004 (0.09 MB TIF)
Figure S5 Osteoblast and Osteoclast Markers are Increased in
DMP1-caPTHR1 Transgenic Mice (A) Quantitative RT-PCR
analysis of osteoblastic genes in tibia from 9-week-old DMP1-
caPTHR1 transgenic mice and wild type littermates. Bars
represent the mean6SD of 3 mice. *p,0.05 vs. WT mice. (B)
In situ hybridization of tibia sections from 10.5-week-old mice with
the indicated probes. (C) Quantitative RT-PCR of osteoclast-
specific genes in tibia of 9-week-old mice. Bars represent the
mean6SD of 3 mice. * p,0.05 vs. WT mice.
Found at: doi:10.1371/journal.pone.0002942.s005 (1.03 MB TIF)
Text S1
Found at: doi:10.1371/journal.pone.0002942.s006 (0.03 MB DOC)
Table S1
Found at: doi:10.1371/journal.pone.0002942.s007 (0.04 MB DOC)
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